By improving detection of atrial fibrillation, more affected individuals can provide researchers with valuable information and a potential signal to treat, said Brent A. Williams, PhD, research investigator focusing on the optimal incorporation of cardiac imaging technologies in clinical practice for Geisinger.
By improving detection of atrial fibrillation, more affected individuals can provide researchers with valuable information and a potential signal to treat, said Brent A. Williams, PhD, research investigator focusing on the optimal incorporation of cardiac imaging technologies in clinical practice for Geisinger.
Transcript
Based on the study results from your session, “Explaining Temporal Trends in Atrial Fibrillation Incidence Rates,” presented at this year’s American Heart Association meeting, what progressions in preventive atrial fibrillation detection were found and what underlying factors remained unmonitored?
A lot of what we noticed in our study, was that the population at risk for atrial fibrillation—so, this group doesn't have any atrial fibrillation yet, but could develop it in the near term–that group of patients are getting heavier; their BM is above 30, the prevalence of that is increasing over time, they're more likely to have hypertension over time. Of course, high BMI and hypertension are 2 of the most common risk factors for atrial fibrillation. So, I think the increasing incidence we saw was largely a combination of the at-risk population having more risk factors, and also more opportunity to diagnose atrial fibrillation. We noticed that there was a sharp increase in least documentation of short-term ECG, 1-time ECG in our at-risk population. More and more atrial fibrillation is being diagnosed via implanted devices like pacemakers and implantable cardioverter defibrillators. So, I think those 2 things in particular are kind of working collectively that we're finding more atrial fibrillation–not that this is necessarily a bad thing. You see that line of new afib [atrial fibrillation] cases going up and it looks bad, but I think we're uncovering what's already there, which can give us a signal to treat.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen